Belite Bio, Inc
NASDAQ:BLTEBiotechnology
Healthcare
$151.02 +0.31%
+$0.46 today
- Market cap
- $6.08B
- Beta
- -1.24
- P/E (TTM)
- -65.9
- EPS (TTM)
- -$2.26
52W Low $56.10High $200.00
Volume 0.14M
Average 0.17M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$84.21M
FY 2025 · Annual
Net Income
-$77.61M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 7.42M | 8.87M | 24.84M | 29.94M | 45.38M |
| Selling, General & Admin | 2.38M | 3.95M | 6.82M | 10.06M | 38.83M |
| Operating Expenses | 9.8M | 12.82M | 31.67M | 40M | 84.21M |
| Depreciation & Amortization | 30K | 198K | 399K | 449K | 464K |
| EBITDA | (9.64M) | (12.43M) | (31.2M) | (35.67M) | (77.15M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (9.8M) | (12.82M) | (31.67M) | (40M) | (84.21M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 5K | 23K | 74K | 3.74M | 0 |
| Interest Expense | 0 | 16K | 25K | 20K | 0 |
| Other Income / Expenses | 131K | 173K | 45K | 3.86M | 6.6M |
| Income Before Tax | (9.67M) | (12.65M) | (31.62M) | (36.14M) | (77.61M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 9K | 6K | 0 |
| Net Income | (9.67M) | (12.65M) | (31.63M) | (36.14M) | (77.61M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.40) | (0.63) | (1.19) | (1.18) | (2.31) |
| EPS (Diluted) | (0.40) | (0.63) | (1.19) | (1.18) | (2.31) |
| 24.1M | 19.98M | 26.59M | 30.54M | 33.54M | |
| 24.1M | 19.98M | 26.59M | 30.54M | 33.54M |
BLTE Earnings Waterfall · TTM
NASDAQ:BLTE · Revenue to Net Income
Key Ratios
EPS$-2.86
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-56.2
P/S Ratio0.0
Analysis
$0 of revenue converted into -$110.9M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.86, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 6-K | 6-K filing | Oct 19, 2026 |
How much revenue does BLTE generate?
Belite Bio, Inc (BLTE) reported $0.00 of revenue in fiscal 2025.
Is BLTE profitable?
Belite Bio, Inc (BLTE) reported -$77.61M of net income.
Continue the stock analysis
Jump to another research area for this company.